Continuos Terlipressin Infusion in Septic Shock

NCT01697410 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1000

Last updated 2014-12-30

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy of terlipressin for treating septic shock.

Conditions

  • Septic Shock

Interventions

DRUG

Terlipressin

continuous infusion of terlipressin (0.66ug/min-2.66ug/min) ,dosage modified acorrding to blood pressure

DRUG

Norepinephrine

continuous infusion with dose 7.5ug/min-30ug/min,modified acorrding to blood pressure

Sponsors & Collaborators

  • Guangdong Province, Department of Science and Technology

    collaborator OTHER_GOV
  • Second Affiliated Hospital, Sun Yat-Sen University

    collaborator OTHER
  • Sixth Affiliated Hospital, Sun Yat-sen University

    collaborator OTHER
  • Chinese PLA General Hospital

    collaborator OTHER
  • Beijing 302 Hospital

    collaborator OTHER
  • Shanghai Changzheng Hospital

    collaborator OTHER
  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    collaborator OTHER
  • Xiangya Hospital of Central South University

    collaborator OTHER
  • Anhui Provincial Hospital

    collaborator OTHER_GOV
  • The First Affiliated Hospital of Bengbu Medical University

    collaborator OTHER
  • Guangxi Medical University

    collaborator OTHER
  • Jinling Hospital, China

    collaborator OTHER
  • West China Hospital

    collaborator OTHER
  • Hainan People's Hospital

    collaborator OTHER
  • Xi'an Jiaotong University

    collaborator OTHER
  • China Medical University, China

    collaborator OTHER
  • First People's Hospital of Foshan

    collaborator OTHER
  • ZhuHai Hospital

    collaborator OTHER
  • First Affiliated Hospital, Sun Yat-Sen University

    lead OTHER

Principal Investigators

  • Guan XiangDong, doctor · first affiliated hospital SunYetSen university

  • liu ZiMeng, M.D · first affiliated hospital ,SunYetSen university

  • Si Xiang, M.D. · first affiliated hospital ,SunYetSen university

  • Chen Juan, M.D. · first affiliated hospital ,SunYetSen university

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2016-01-31
Completion
2016-01-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01697410 on ClinicalTrials.gov